BRKR
Bruker Corporation
BRKR has the edge over NVO overall, supported by stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
BRKR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Healthy | |
| Weak |
BRKR's cash flow is currently healthy, and its revenue is stable, but its profitability and balance sheet are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
BRKR PE Valuation
BRKR has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
BRKR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect BRKR's earnings to grow and its profitability to improve, with its revenue holding steady.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
BRKR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.34 | — |
| Q3 2026 | -$1.10 | -$0.94 |
| Q2 2026 | -$0.70 | -235% |
| Q1 2026 | -$0.24 | -146% |
| Q4 2025 | -$0.15 | -120% |
| Q3 2022 | $1.82 | +3.4% |
| Q2 2022 | $1.80 | +17% |
| Q1 2022 | $1.85 | +40% |
| Q4 2021 | $1.81 | +77% |
BRKR lost $1.10 per share over the past year, and its loss has widened in each of the last three quarters.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over BRKR on earnings quality, reporting a profit while its opponent remains loss making.
BRKR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $874M | +1.6% |
| Q2 2026 | $838.5M | +5.2% |
| Q1 2026 | $823.4M | +2.7% |
| Q4 2025 | $977.2M | -0.2% |
| Q3 2025 | $860.5M | -0.5% |
| Q2 2025 | $797.4M | -0.4% |
| Q1 2025 | $801.4M | +11% |
| Q4 2024 | $979.6M | +15% |
BRKR's revenue grew through 2024 and has held roughly level since: $874M last quarter, up 1.6% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -10% | -4.4 points |
| Q2 2026 | -7.8% | -9.3 points |
| Q1 2026 | 1.2% | -2.7 points |
| Q4 2025 | 7.8% | +0.4 points |
| Q3 2025 | -6% | -14 points |
| Q2 2025 | 1.5% | -4.5 points |
| Q1 2025 | 4% | -5 points |
| Q4 2024 | 7.4% | -4.7 points |
BRKR's operating margin was −10% last quarter, down 4.4 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over BRKR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over BRKR on profitability, with a higher operating margin.
BRKR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $96.7M | +$150.8M |
| Q2 2026 | -$106.2M | +$42.6M |
| Q1 2026 | $47M | +21% |
| Q4 2025 | $207.2M | +35% |
| Q3 2025 | -$54.1M | -1033% |
| Q2 2025 | -$148.8M | -$125.3M |
| Q1 2025 | $39M | +9650% |
| Q4 2024 | $153.3M | -12% |
BRKR's free cash flow has turned positive again: $245M over the past year, against −$11M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
BRKR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +200K shares |
| 1 year | +0.5% | +700K shares |
| 3 years | -1.9% | -2.9M shares |
BRKR has 153M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $10M |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over BRKR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
BRKR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 10.0x | High |
| Q2 2026 | 8.2x | High |
| Q1 2026 | 5.6x | High |
| Q4 2025 | 5.4x | High |
| Q3 2025 | 6.2x | High |
| Q2 2025 | 5.9x | High |
| Q1 2025 | 4.6x | High |
| Q4 2024 | 4.4x | High |
BRKR's net debt is about 10 years of its operating earnings (EBITDA), up from 6.2 years a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over BRKR on leverage, with a lower net debt burden relative to earnings.
BRKR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.3 | Neutral |
| Stochastic | 52.9 | Neutral |
BRKR's weekly RSI is 55 (neutral) and its Stochastic is 53 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
BRKR PE vs Healthcare Sector
| Metric | BRKR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BRKR has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BRKR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $59.7 | 1.1% above |
| 20 week MA | $59.1 | 2.1% above |
| 50 week MA | $50.4 | 20% above |
| 100 week MA | $46.4 | 30% above |
| 200 week MA | $58.3 | 3.6% above |
BRKR has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
BRKR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.0 | $54.3 | +6.6% |
| 2021 | $54.3 | $80.3 | +48% |
| 2022 | $80.3 | $66.5 | -17% |
| 2023 | $66.5 | $73.5 | +10% |
| 2024 | $73.5 | $58.4 | -21% |
| 2025 | $58.4 | $48.0 | -18% |
| 2026 YTD | $48.0 | $60.3 | +26% |
BRKR has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.